Time points | Eye symptoms | Visual field | ERG | VEP | OCT | Ophthalmoscope examination | Fundus fluorescein angiography | Visual acuity |
---|---|---|---|---|---|---|---|---|
December 6th, 2017 (during chemotherapy) | Progressive visual loss | – | – | – | – | Optic disc edema, fuzzy boundary and linear hemorrhages. | – | 0.4 |
December 29th, 2017 (during chemotherapy) | Progressive visual loss | – | – | – | – | Optic disc edema, fuzzy boundary and linear hemorrhages. | – | 0.3 |
January 5th, 2018 (1 week after chemotherapy) | Progressive visual loss | Severe visual field defects | – | – | Thinner ILM-RPE at superior side and nasal side | The upper part of the optic disc becoming gray, optic disc edema subsiding and residual retinal hemorrhage on the inferior rim; creases, depigmented macules and hard exudate in the macular area. | Capillary underdevelopment at the nasal and superior temporal area of optic disc in the early phase and capillary fluorescein leakage in the late phase | 0.3 |
January 25th, 2018 (1 month after chemotherapy) | Improved vision | Obviously improved visual field. | Normal amplitudes of a-type wave, b-type wave and P1-type wave. | Lengthened incubation period of P100-type wave in P-VEP test. | Secondary macular epiretinal membrane | Gray optic disc without edema and with clear boundary. | – | 0.4 |
March 28th, 2018 (3 months after chemotherapy) | Improved vision | – | – | Normal incubation period of P2-type wave. | Secondary macular epiretinal membrane. | The optic disc becoming not so gray as before. | – | 0.5 |
August 13th, 2018 (7.5 months after chemotherapy) | Improved vision | Dramatically improved visual field. | – | – | – | – | – | 0.5 |